Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella
March 04 2019 - 7:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment
of Dr. Karen Smith to the Company’s Board of Directors, filling the
seat being vacated by the retirement of Dr. Jacques Gonella.
Dr. Smith has over 20 years of biopharmaceutical industry
experience in the United States, Europe, Canada and Asia, and
currently serves as Chief Executive Officer for Eliminate Cancer
(ECI), a cutting-edge oncology R&D and venture
organization.
Leonard S. Jacob, M.D., Ph.D., Chairman of the
Board of Antares Pharma, stated, “We are pleased to announce the
addition of another seasoned pharmaceutical executive to the
Antares Board of Directors. We believe Dr. Smith’s background
in drug development and product registration will benefit our
organization as we continue to expand the Company’s pipeline.
We look forward to Karen’s contributions.”
Dr. Smith has overseen more than 60 clinical
trials and more than 20 regulatory approvals leading to product
launches across diverse therapeutic areas including oncology, rare
disease, cardiology, dermatology neuroscience and
anti-infectives. In addition to R&D and pipeline
development, Karen’s successful record of business development
includes the acquisition of U.S. and international companies,
divestitures and negotiating partnership deals between biotech and
pharma. Prior to joining ECI, Karen served as Executive Vice
President, Global Head R&D, and Chief Medical Officer of Jazz
Pharmaceuticals, Inc., and also held senior leadership positions at
Allergan plc, AstraZeneca and Bristol-Myers Squibb. She is
currently a member of the Board of Directors of Acceleron Pharma,
ECI and Sangamo Therapeutics. Dr. Smith earned an MD from the
University of Warwick (UK), PhD in Molecular Oncology from UCLA
(USA) and University of Western Australia (Australia), an MBA from
the University of New England in Australia and LLM (Masters in Law)
from the University of Salford (UK).
Dr. Jacob continued, “The Board of Directors
would like to thank Dr. Gonella for eighteen years of dedicated
service, first as the founder of Antares Pharma and also as a
significant contributor to the development of our Company. He
served for eight years as our first Chairman of the Board of
Directors. Dr. Gonella’s lengthy experience in R&D,
operating and financial management as well as his knowledge
concerning public companies has provided valuable insight regarding
the Company’s operations. We wish him well in his
retirement.”
About Antares Pharma
Antares Pharma, Inc. is a combination drug
device company focused on the development and commercialization of
self-administered parenteral pharmaceutical products using advanced
drug delivery auto injector technology. The Company has a
portfolio of proprietary and partnered commercial products with
several product candidates in advanced stages of development, as
well as significant strategic alliances with industry leading
pharmaceutical companies including Teva Pharmaceutical Industries,
Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc.
(Pfizer). Antares Pharma’s proprietary products include
XYOSTED™ (testosterone enanthate) injection, OTREXUP®
(methotrexate) injection for subcutaneous use and Sumatriptan
Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the contributions of
Dr. Karen Smith and increased shareholder value; market acceptance,
adequate reimbursement coverage and commercial success of XYOSTED™
and future revenue from the same; market acceptance of Teva’s
generic epinephrine auto-injector product and future revenue from
the same; successful completion of the transaction with Ferring
International Center, S.A.; future market acceptance and revenue
from Makena® subcutaneous auto injector; Teva’s ability to
successfully commercialize VIBEX® Sumatriptan Injection USP and the
amount of revenue from the same; continued growth of prescriptions
and sales of OTREXUP®; the timing and results of the
Company’s or its partners’ research projects or clinical trials of
product candidates in development including projects with Teva and
Pfizer; actions by the FDA or other regulatory agencies with
respect to the Company’s products or product candidates of its
partners; continued growth in product, development, licensing and
royalty revenue; achievement of the 2019 revenue guidance; the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities and
other statements regarding matters that are not historical facts,
and involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not
to place undue reliance on the forward-looking statements contained
in this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:
Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024